Device Trial Radar · NCT07911488
The Encora X1™ in a Real World Observational Study
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Nov 2031
Study completion Aug 2032
Sponsor
- Lead sponsor
- Encora, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 2, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research is a post-market study designed to evaluate the long-term, real-world impact of the Encora X1™ on your daily life. The Encora X1™ is a FDA-cleared, wrist-worn, non-invasive neurostimulator device that delivers personalized mechanical stimulation to aid in the relief of hand tremors in adults with essential tremor. A non-invasive device is a device that stays outside of the body. It is not implanted and does not penetrate the skin. Neurostimulation means that the device uses targeted electrical or magnetic pulses to stimulate activity in the nervous system. This study aims to understand how it improves your ability to perform daily activities and your overall satisfaction with the device over a 36-month period. Your feedback will help researchers understand how the device is used over a long period of time in a home environment and improve the delivery of care for individuals with Essential Tremor.
Conditions
- Essential Tremor
Interventions
Encora X1Device
Encora X1 is indicated to aid in the relief of hand tremors in the treated limb during stimulation in adults with essential tremor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Bain & Findley Activities of Daily Living (BF-ADL) composite score at each scheduled assessment.Time frame: Baseline to Week 1, Months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and Post Treatment Weeks 1, 4 and 8
- Change from baseline in the TETRAS PRO composite score at each scheduled assessment.Time frame: Baseline to Week 1, Months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, and 36
- Change from baseline in the QUEST PRO weighted index score at each scheduled assessment.Time frame: Baseline to Week 1, Months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, and 36
11 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Encora Therapeutics
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.